Cargando…

P43 In vitro activity of cefiderocol and comparators against Gram-negative pathogens: ARTEMIS study in the UK

OBJECTIVES: Cefiderocol (CFDC) is a novel siderophore cephalosporin approved in Europe for the treatment of infections caused by aerobic Gram-negative (GN) bacteria in adults with limited treatment options. The aim of the ARTEMIS study was to evaluate the in vitro activity of CFDC and comparators ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wareham, D., Attwood, M., Casey, A. L., Coyne, M., Hughes, D., Lister, M., Nahl, J., Perry, J. D., Henriksen, A. Santerre, Longshaw, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Posters Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039995/ http://dx.doi.org/10.1093/jacamr/dlac004.042

Ejemplares similares

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

660. In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021
por: Santerre Henriksen, Anne Laurence, et al.
Publicado: (2022)

Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance
por: Longshaw, Christopher M, et al.
Publicado: (2022)

Evidence for Efficacy of Cefiderocol against OXA-48-Containing Isolates from the APEKS-NP and CREDIBLE-CR Trials
por: Longshaw, Christopher, et al.
Publicado: (2022)

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium
por: Oueslati, Saoussen, et al.
Publicado: (2022)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
por: Yamano, Yoshinori, et al.
Publicado: (2022)

Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
por: Pybus, Christine A., et al.
Publicado: (2021)

The ARTEMIS mission
por: Russell, Christopher, et al.
Publicado: (2014)

679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)
por: Longshaw, Christopher, et al.
Publicado: (2019)

719. Cefiderocol Retains Anti-Biofilm Activity in MDR Gram-Negative Pathogens
por: Pybus, Christine A, et al.
Publicado: (2019)

Structure-Specific nuclease activities of Artemis and the Artemis: DNA-PKcs complex
por: Chang, Howard H.Y., et al.
Publicado: (2016)

603. Determining Effect of Media and Disk Source on Reproducibility and Relationship between Broth Microdilution and Disk Diffusion Testing of Cefiderocol
por: Takemura, Miki, et al.
Publicado: (2023)

2118. Comparative Analysis of Cefiderocol Mono- and Combination Therapy for Multi-Drug Resistant Gram-negative Infections
por: Ghali, Amer El, et al.
Publicado: (2023)

2762. Activity of Cefiderocol and Comparator Agents Against Difficult to Treat Resistance (DTR) Gram-negative Isolates, Collected During 2020-2022 as Part of SENTRY Antimicrobial Surveillance Program
por: DeJonge, Boudewijn L, et al.
Publicado: (2023)

Becoming Artemis’s Mother
por: McKinley, Sophia K.
Publicado: (2021)

Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

P35 Heteroresistance to cefiderocol in clinical Gram-negative isolates
por: Watson, Celeste, et al.
Publicado: (2023)

Cefiderocol: EUCAST criteria for disc diffusion and broth microdilution for antimicrobial susceptibility testing
por: Matuschek, Erika, et al.
Publicado: (2022)

In Vitro Activity of Cefiderocol against Multi-Drug Resistant Carbapenemase-Producing Gram-Negative Pathogens
por: Boyd, Sandra, et al.
Publicado: (2017)

Cefiderocol: A Novel Agent for the Management of Multidrug-Resistant Gram-Negative Organisms
por: Wu, Janet Y., et al.
Publicado: (2020)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
por: Syed, Yahiya Y.
Publicado: (2021)

Performance evaluation of the UMIC(®) Cefiderocol to determine MIC in Gram-negative bacteria
por: Dortet, Laurent, et al.
Publicado: (2023)

Susceptibility of cefiderocol and other antibiotics against carbapenem-resistant, Gram-negative bacteria
por: Wang, Yifan, et al.
Publicado: (2022)

Cefiderocol, a new antibiotic against multidrug-resistant Gram-negative bacteria
por: Silva, José Tiago, et al.
Publicado: (2021)

Case series of cefiderocol for salvage therapy in carbapenem-resistant Gram-negative infections
por: Gavaghan, Victoria, et al.
Publicado: (2022)

P44 Nosocomial neurosurgical meningitis due to XDR Pseudomonas aeruginosa: clinical experience with cefiderocol
por: Stevenson, D. R., et al.
Publicado: (2022)

2790. Activity of Cefiderocol and Comparator Agents Against Pediatric Isolates of Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii-calcoaceticus species complex, and Stenotrophomonas maltophilia from the SENTRY Surveillance Program (2020-2022)
por: Nguyen, Sean T, et al.
Publicado: (2023)

In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, against Multidrug-Resistant Gram-Negative Bacteria
por: Mushtaq, Shazad, et al.
Publicado: (2020)

Assessment of In Vitro Cefiderocol Susceptibility and Comparators against an Epidemiologically Diverse Collection of Acinetobacter baumannii Clinical Isolates
por: Ballesté-Delpierre, Clara, et al.
Publicado: (2022)

648. Cefiderocol as Rescue Therapy for Pseudomonas aeruginosa and Other Difficult-To-Treat Gram-Negative Infections
por: Chou, Andrew, et al.
Publicado: (2022)

Cefiderocol
por: Soriano, María Cruz, et al.
Publicado: (2022)

Carbapenem-Resistant Acinetobacter spp Infection in Critically Ill Patients With Limited Treatment Options: A Descriptive Study of Cefiderocol Therapy During the COVID-19 Pandemic
por: Giannella, Maddalena, et al.
Publicado: (2023)

ARTEMIS stabilizes the genome and modulates proliferative responses in multipotent mesenchymal cells
por: Maas, Sarah A, et al.
Publicado: (2010)

1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant Pseudomonas aeruginosa Infections under Cefiderocol Compassionate Use Program
por: Satlin, Michael J, et al.
Publicado: (2021)

Characterization and Evaluation of the Artemis Camera for Fluorescence-Guided Cancer Surgery
por: van Driel, P. B. A. A., et al.
Publicado: (2014)

Structural and mechanistic insights into the Artemis endonuclease and strategies for its inhibition
por: Yosaatmadja, Yuliana, et al.
Publicado: (2021)

721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
por: Iregui, Alejandro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4ro2ef6dfdnnkeapvc8ak8rncj